Hemispherx BioPharma, Inc (HEB) Sees Significant Growth in Short Interest
Hemispherx BioPharma, Inc (NYSE:HEB) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 286,805 shares, an increase of 68.7% from the August 31st total of 170,008 shares. Approximately 1.4% of the shares of the company are short sold. Based on an average daily trading volume, of 168,879 shares, the days-to-cover ratio is currently 1.7 days.
Hemispherx BioPharma (NYSE:HEB) opened at 1.26 on Friday. The firm’s market cap is $26.14 million. The company has a 50-day moving average of $1.57 and a 200 day moving average of $1.56. Hemispherx BioPharma has a one year low of $0.72 and a one year high of $2.64.
Hemispherx BioPharma (NYSE:HEB) last announced its earnings results on Monday, August 15th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter. During the same quarter in the prior year, the firm posted ($0.02) earnings per share.
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Stock Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related stocks with our FREE daily email newsletter.